Last reviewed · How we verify
NCT06747481
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
trial in Pancreatic Cancer, Adult in 323 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | University of Las Palmas de Gran Canaria |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 323 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across Spain |
Conditions studied
- Pancreatic Cancer, Adult — all drugs for Pancreatic Cancer, Adult →
- Perineural Invasion — all drugs for Perineural Invasion →
- Neutrophil-to-Lymphocyte Ratio — all drugs for Neutrophil-to-Lymphocyte Ratio →
- CA 19.9 — all drugs for CA 19.9 →
Sponsor
University of Las Palmas de Gran Canaria
Who can join
Eligibility, any sex, with Pancreatic Cancer, Adult or Perineural Invasion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain. This disease is associated with a poor prognosis, reflected by a 5-year survival rate of less than 5% when all stages are grouped together. Several prognostic factors for pancreatic cancer have been identified. The most relevant include preoperative levels of carbohydrate antigen 19-9 (CA 19.9), surgical margins after resection, venous and/or arterial vascular involvement, and histopathological features such as affected locoregional lymph nodes, or perineural and lymphovascular invasion. Among all these factors, perineural invasion may be the primary independent factor affecting prognosis, particularly in patients with relatively favorable pathological features. The identification of perineural invasion before surgery could influence the clinical management of these patients. It may facilitate risk stratification, allowing the identification of patients who would benefit most from neoadjuvant treatments or more aggressive surgical procedures, such as vascular resections. However, perineural involvement is very difficult to detect preoperatively. Only a few studies have analyzed the possible relationship between CA 19.9 and perineural invasion, and their results are inconsistent. Alternatively, some studies have demonstrated the utility of preoperative multidetector computed tomography in detecting extrapancreatic perineural invasion. However, these radiological tests are still not useful for directly detecting microscopic perineural invasion, especially in early stages. On the other hand, in recent years, evidence has supported that the systemic inflammatory response may play an important role in the prognosis of different malignancies. Among these inflammatory markers, the neutrophil-to-lymphocyte ratio (NLR) has gained prominence. Regarding pancreatic cancer, many studies suggest that elevated preoperative NLR levels are associated with a worse prognosis. However, no studies have yet been published analyzing a possible relationship between this inflammatory marker and perineural invasion. The main objective of this study is to correlate the neutrophil-to-lymphocyte ratio (NLR) and CA 19.9 with histopathologically confirmed perineural invasion and, in this way, investigate these data as potential preoperative markers of perineural invasion in pancreatic cancer. Our working hypothesis is that preoperative NLR and CA 19.9 are potential markers of perineural invasion. As secondary objectives, we aim to study the effect of neoadjuvant therapy on inflammatory markers (NLR) and tumor markers (CEA and CA 19.9) in pancreatic cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions.
Lovecek M, Dirimtekin E, Garajová I, Gasparini G, et al · · 2025 · cited 2× · PMID 40981722 · DOI 10.1002/ueg2.70118
Verify or expand the search:
- PubMed search for NCT06747481
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer, Adult
Currently open trials in the same condition.
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
- NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticod · NA · recruiting
- NCT06584227 — Adebrelimab and Chidamide for Pancreatic Cancer · Phase 2 · recruiting
- NCT06388967 — Pancreatic Cancer Detection Consortium · recruiting
- NCT06822413 — Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis · recruiting
Other University of Las Palmas de Gran Canaria trials
Trials by the same sponsor.
- NCT04962737 — Non-invasive Neuromodulation NESA Through Somatosensory Evoked Potentials and Sympathetic-cutaneous Responses · NA · not yet recruiting
- NCT06417450 — Usefulness of NESA Microcurrents in the Treatment of Children With Autism Spectrum Disorders · NA · completed
- NCT06134999 — Study of Patients With Knee Prostheses Treated With Noninvasive Neuromodulation · NA · completed
- NCT06138158 — Improvement of Fear-avoidance Beliefs in Patients With Chronic Low Back Pain · NA · completed
- NCT05800431 — NESA Microcurrents on Quality of Life in Geriatric Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06747481 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Las Palmas de Gran Canaria
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06747481.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing